Section Arrow
Quote
OBIO.NASDAQ
- Orchestra BioMed Holdings
Quotes are at least 15-min delayed:2026/04/23 14:03 EDT
Regular Hours
Last
 4.13
-0.08 (-1.90%)
Day High 
4.23 
Prev. Close
4.21 
1-M High
4.83 
Volume 
57.08K 
Bid
4.1
Ask
4.16
Day Low
4.09 
Open
4.22 
1-M Low
4.04 
Market Cap 
246.37M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 4.36 
20-SMA 4.33 
50-SMA 4.33 
52-W High 5.424 
52-W Low 2.2 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.11/-1.53
Enterprise Value
261.58M
Balance Sheet
Book Value Per Share
0.92
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
33.48M
Operating Revenue Per Share
0.00
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ALTAltimmune2.86-0.61-17.58%-- 
REPLReplimune Group2.75+0.48+21.15%-- 
VRAXVirax Biolabs Group Limited0.15255+0.01755+13.00%-- 
IOVAIovance Biotherapeutics3.435-0.095-2.69%-- 
RXRXRecursion Pharmaceuticals3.495-0.235-6.30%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. Ithas one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.